We demonstrated that these drugs downregulate MCL1 activity via distinct mechanisms and synergize significantly with the BCLXL inhibitor, leading to enhanced anti-tumor activity with tolerable toxicity in preclinical GC models. Here, BCL2L1 is linked to gastric cancer.